Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ASP3700 in Healthy Men
NCT02155504Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- May 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP3700 in osteoarthritis (OA) (4 arms), sponsored by Astellas Pharma. Primary endpoints: Safety as assessed by adverse events up to 16 days, Safety as assessed by vital signs up to 16 days and 10 more. Started May 2014; status: completed.
02
Drugs
ASP3700
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02155504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155504.